During the past decade, Austin Retina Associates conducted 52 clinical trials. In the 10-year time frame, 52 clinical trials started and 26 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 20 clinical trials were completed. i.e. 74.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Austin Retina Associates" #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Jaeb Center for Health Research" with 10 trials sponsored, "Clearside Biomedical, Inc." with 5 trials sponsored, "Genentech, Inc." with 5 trials sponsored and "Kodiak Sciences Inc" with 5 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Austin Retina Associates" #1 collaborator was "National Eye Institute (NEI)" with 9 trials as a collaborator, "National Institutes of Health (NIH)" with 6 trials as a collaborator, "Regeneron Pharmaceuticals" with 4 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 3 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Austin Retina Associates" are "Diabetic Macular Edema" (14 trials), "Geographic Atrophy" (8 trials), "Macular Degeneration" (8 trials), "Diabetic Retinopathy" (5 trials) and "Macular Edema" (5 trials). Many other conditions were trialed in "Austin Retina Associates" in a lesser frequency.

Most popular intervention types in "Austin Retina Associates" are "Drug" (57 trials), "Other" (17 trials), "Procedure" (7 trials), "Device" (5 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (13 trials), "Aflibercept" (9 trials), "Faricimab" (8 trials), "Placebo" (6 trials) and "KSI-301" (5 trials). Other intervention names were less common.

The vast majority of trials in "Austin Retina Associates" are 62 trials for "All" genders.

Currently, there are NaN active trials in "Austin Retina Associates". undefined are not yet recruiting, 8 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Austin Retina Associates, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Austin Retina Associates, 1 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".